Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › Panitumumab

Panitumumab

0 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of Panitumumab

52 trials tracked of Panitumumab: 7 in phase 3 or 4.

52Trials tracked
7Phase 3 & 4
0Recruiting
0With published results
Phase distribution
Phase 3 7 Phase 2 42 Phase 1 2 Other / NA 1
  1. Phase 3 ASPECCT: A Study of Panitumumab Efficacy and Safety Compared to Cetuximab in Patients With KRAS Wild-Type Metastatic Colorectal Cancer Completed
  2. Phase 3 Evaluating Panitumumab (ABX-EGF) Plus Best Supportive Care Versus Best Supportive Care in Patients With Metastatic Colorectal Cancer Completed
  3. Phase 3 Comparison of Treatment Effect of Chemotherapy With Panitumumab to Chemotherapy Alone Completed
  4. Phase 3 Comparison of Survival Benefit of Panitumumab With Supportive Care to Best Supportive Care Alone in Patients With Metastatic Colorectal Cancer Completed
  5. Phase 3 PRIME: Panitumumab Randomized Trial In Combination With Chemotherapy for Metastatic Colorectal Cancer to Determine Efficacy Completed
  6. Phase 3 Radiation + Cisplatin or Panitumumab in Locally Advanced Stage III or Stage IV Head and Neck Cancer Completed
Show 44 more trials
  1. Phase 3 PACCE: Panitumumab Advanced Colorectal Cancer Evaluation Study Completed
  2. Phase 2 Evaluating Panitumumab (ABX-EGF) Monotherapy in Patients With Metastatic Colorectal Cancer Following Treatment With Fluoropyrimidine, Irinotecan, and Oxaliplatin Chemotherapy Completed
  3. Phase 2 Panitumumab (ABX-EGF) Monotherapy in Patients With Metastatic Colorectal Cancer Completed
  4. Phase 2 Panitumumab and Chemotherapy in Patients With Advanced Colorectal Cancer After Prior Therapy With Bevacizumab Completed
  5. Phase 2 Study to Evaluate Mechanisms of Acquired Resistance to Panitumumab Completed
  6. Phase 2 Radiotherapy Plus Panitumumab Compared to Chemoradiotherapy With Unresected, Locally Advanced Squamous Cell Carcinoma of the Head and Neck Completed
  7. Phase 2 Erlotinib and Gemcitabine With or Without Panitumumab in Treating Patients With Metastatic Pancreatic Cancer Completed
  8. Phase 2 Panitumumab, Docetaxel, Cisplatin, Radiation Therapy, and Surgery in Treating Patients With Newly Diagnosed, Locally Advanced Esophageal Cancer or Cancer of the Gastroesophageal Junction Completed
  9. Phase 2 FOLFOXIRI Plus Panitumumab Patients With Metastatic KRAS Wild-Type Colorectal Cancer With Liver Metastases Only Completed
  10. Phase 2 PARTNER: Panitumumab Added to Regimen for Treatment of Head aNd Neck Cancer Evaluation of Response Completed
  11. Phase 2 Panitumumab in Cetuximab Refractory KRAS Wild-Type Colorectal Cancer Completed
  12. Phase 2 A Study of BBI608 in Adult Patients With Advanced Colorectal Cancer Completed
  13. Phase 2 PRISM (Panitumumab Regimen In Second-line Monotherapy of Head and Neck Cancer) Completed
  14. Phase 2 A Randomized Phase 2 Pharmacokinetic Trial of Chemotherapy With or Without Panitumumab in Patients With Metastatic and/or Recurrent Squamous Cell Carcinoma of the Head and Neck Completed
  15. Phase 2 Study of Hepatic Arterial Infusion With Intravenous Irinotecan, 5FU and Leucovorin With or Without Panitumumab, in Patients With Wild Type RAS Who Have Resected Hepatic Metastases From Colorectal Cancer Completed
  16. Phase 2 Trial of Postoperative Radiation, Cisplatin, and Panitumumab in Locally Advanced Head and Neck Cancer Completed
  17. Phase 2 SPIRITT - Second-Line Panitumumab Irinotecan Treatment Trial Completed
  18. Phase 2 Chemotherapy and Radiation Therapy With or Without Panitumumab in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer Completed
  19. Phase 2 Panitumumab Regimen Evaluation in Colorectal Cancer to Estimate Primary Response to Treatment Completed
  20. Phase 2 Panitumumab and Irinotecan as Third-Line Therapy in Treating Patients With Metastatic Colorectal Cancer Completed
  21. Phase 2 Panitumumab, Nab-paclitaxel and Carboplatin for HER2 Negative Inflammatory Breast Cancer Completed
  22. Phase 2 Study of Addition of Panitumumab to Chemoradiation Therapy in Patients With Locally Advanced Head and Neck Cancer Completed
  23. Phase 2 BRAF/MEK/EGFR Inhibitor Combination Study in Colorectal Cancer (CRC) Completed
  24. Phase 2 Radiochemotherapy With Panitumumab in the Localised Epidermoid Carcinoma of the Anus Completed
  25. Phase 2 Phase Ib/II Study of Efficacy and Safety of MEK162 and Panitumumab, in Adult mCRC Patients With Mutant or Wild-type RAS Tumors Completed
  26. Phase 2 Phase I/II Study of Panitumumab, Capecitabine and Oxaliplatin w EBRT for Esophageal Cancer Completed
  27. Phase 2 PhII Trial Panitumumab, Nivolumab, Ipilimumab in Kras/Nras/BRAF Wild-type MSS Refractory mCRC Completed
  28. Phase 2 PEAK: Panitumumab Plus mFOLFOX6 vs. Bevacizumab Plus mFOLFOX6 for First Line Treatment of Metastatic Colorectal Cancer (mCRC) Patients With Wild-Type Kirsten Rat Sarcoma-2 Virus (KRAS) Tumors Completed
  29. Phase 2 Gemcitabine, Oxaliplatin and Panitumumab in Kras/B-raf Wild-Type Biliary Track and Gallbladder Cancer Completed
  30. Phase 2 CAPOX in KRAS Wild-Type Advanced Adenocarcinoma of the Small Bowel or Ampulla of Vater Completed
  31. Phase 2 Panitumumab Combination Study With Rilotumumab or Ganitumab in Wild-type Kirsten Rat Sarcoma Virus Oncogene Homolog (KRAS) Metastatic Colorectal Cancer (mCRC) Completed
  32. Phase 2 Carboplatin, Pemetrexed, and Panitumumab in Patients With Advanced Non-Squamous K-ras Wild Type NSCLC Completed
  33. Phase 2 Novel PET/CT Imaging Biomarkers of CB-839 in Combination With Panitumumab and Irinotecan in Patients With Metastatic and Refractory RAS Wildtype Colorectal Cancer Completed
  34. Phase 2 Study to Evaluate Motesanib With or Without Carboplatin/Paclitaxel or Panitumumab in the Treatment of Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Completed
  35. Phase 2 Panitumumab, Chemotherapy, and External-Beam Radiation Therapy in Treating Patients With Locally Advanced Pancreatic Cancer That Cannot be Removed by Surgery Completed
  36. Phase 2 Evaluating Panitumumab (ABX-EGF) in Patients With Metastatic Colorectal Cancer Completed
  37. Phase 2 Conatumumab/Panitumumab Combination Metastatic Colorectal Cancer Study Completed
  38. Phase 2 Panitumumab, Gemcitabine and Carboplatin in Triple-Negative Metastatic Breast Cancer Completed
  39. Phase 2 Panitumumab Plus FOLFIRI in First-line Treatment of Metastatic Colorectal Cancer Completed
  40. Phase 2 Women's MoonShot: Neoadjuvant Treatment With PaCT for Patients With Locally Advanced TNBC Completed
  41. Phase 2 Phase II Study of Irinotecan and Panitumumab Completed
  42. Phase 2 Skin Toxicity Treatment in Metastatic Colorectal Cancer (mCRC) Patients Receiving Panitumumab + Irinotecan-based Therapy Completed
  43. Phase 2 Dual Epidermal Growth Factor Receptor Inhibition With Erlotinib and Panitumumab With or Without Chemotherapy for Advanced Colorectal Cancer Completed
  44. Phase 1 Panitumumab in Children With Solid Tumors Completed

Showing the 50 most-cited and recently-updated of 52 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
No published articles yet for this medication. Check back soon.